ALIVUS — Alivus Life Sciences Cashflow Statement
0.000.00%
- IN₹124.37bn
- IN₹119.05bn
- IN₹23.87bn
- 88
- 17
- 61
- 58
Annual cashflow statement for Alivus Life Sciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | C2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 4,709 | 5,649 | 6,286 | 6,313 | 6,541 |
Depreciation | |||||
Non-Cash Items | 999 | 331 | 25.3 | 258 | 201 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -2,161 | -383 | -3,672 | -2,970 | -3,433 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 3,881 | 5,976 | 3,060 | 4,135 | 3,915 |
Capital Expenditures | -680 | -1,322 | -1,628 | -1,290 | -1,662 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -7.41 | 99.4 | 161 | 125 | -4,495 |
Sale of Fixed Assets | |||||
Change in Net Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -687 | -1,222 | -1,467 | -1,165 | -6,156 |
Financing Cash Flow Items | — | -0.72 | -5.47 | -15.5 | -24.1 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -2,138 | -788 | -3,876 | -2,794 | -62.3 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 1,056 | 3,966 | -2,283 | 176 | -2,304 |